Head to Head Comparison: BioXcel Therapeutics (NASDAQ:BTAI) and BioCryst Pharmaceuticals (NASDAQ:BCRX)

BioXcel Therapeutics (NASDAQ:BTAI) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership and earnings.

Valuation and Earnings

This table compares BioXcel Therapeutics and BioCryst Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioXcel Therapeutics	$640,000.00	3.63	-$69.90 million	($3.79)	-0.02
BioCryst Pharmaceuticals	$874.84 million	2.39	$263.86 million	($1.50)	-5.45

BioCryst Pharmaceuticals has higher revenue and earnings than BioXcel Therapeutics. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than BioXcel Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent recommendations for BioXcel Therapeutics and BioCryst Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioXcel Therapeutics	1	1	2	0	2.25
BioCryst Pharmaceuticals	1	4	7	0	2.50

BioXcel Therapeutics currently has a consensus price target of $11.00, suggesting a potential upside of 14,744.80%. BioCryst Pharmaceuticals has a consensus price target of $20.50, suggesting a potential upside of 150.92%. Given BioXcel Therapeutics’ higher possible upside, equities research analysts clearly believe BioXcel Therapeutics is more favorable than BioCryst Pharmaceuticals.

Insider & Institutional Ownership

30.7% of BioXcel Therapeutics shares are owned by institutional investors. Comparatively, 85.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. 3.7% of BioXcel Therapeutics shares are owned by insiders. Comparatively, 3.8% of BioCryst Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares BioXcel Therapeutics and BioCryst Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioXcel Therapeutics	-9,549.87%	N/A	-185.82%
BioCryst Pharmaceuticals	-40.90%	-86.89%	66.37%

Volatility & Risk

BioXcel Therapeutics has a beta of 0.19, suggesting that its share price is 81% less volatile than the S&P 500. Comparatively, BioCryst Pharmaceuticals has a beta of 0.55, suggesting that its share price is 45% less volatile than the S&P 500.

Summary

BioCryst Pharmaceuticals beats BioXcel Therapeutics on 10 of the 14 factors compared between the two stocks.

About BioXcel Therapeutics

BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.